Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Ji Hyun | - |
dc.contributor.author | You, Gun Lyung | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Hong, Min Hee | - |
dc.contributor.author | Han, Ji-Youn | - |
dc.contributor.author | Ock, Chan-Young | - |
dc.contributor.author | Lee, Jong-Seok | - |
dc.contributor.author | Oh, In Jae | - |
dc.contributor.author | Lee, Shin Yup | - |
dc.contributor.author | Kim, Cheol Hyeon | - |
dc.contributor.author | Min, Young Joo | - |
dc.contributor.author | Choi, Yoon Hee | - |
dc.contributor.author | Ryu, Jeong-Seon | - |
dc.contributor.author | Park, Sun Hyo | - |
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Shim, Byoung-Yong | - |
dc.contributor.author | Lee, Ki Hyeong | - |
dc.contributor.author | Lee, Sung Yong | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Yi, Jiun | - |
dc.contributor.author | Choi, Su Kyung | - |
dc.contributor.author | An, Hyonggin | - |
dc.contributor.author | Kang, Jin Hyoung | - |
dc.date.accessioned | 2022-02-25T19:40:30Z | - |
dc.date.available | 2022-02-25T19:40:30Z | - |
dc.date.created | 2022-02-09 | - |
dc.date.issued | 2021-08 | - |
dc.identifier.issn | 0171-5216 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136894 | - |
dc.description.abstract | Purpose Although immune-checkpoint inhibitors have become a new therapeutic option for recurrent/metastatic non-small cell lung cancers (R/M-NSCLC), its clinical benefit in the real-world is still unclear. Methods We investigated 1181 Korean patients with programmed death-1 ligand 1 (PD-L1)-positive [tumor proportion score (TPS) >= 10% by the SP263 assay or >= 50% by the 22C3 assay] R/M-NSCLC treated with pembrolizumab or nivolumab after failure of platinum-based chemotherapy. Results The median age was 67 years, 13% of patients had ECOG-PS >= 2, and 27% were never-smokers. Adenocarcinoma was predominant (61%) and 18.1% harbored an EGFR activating mutation or ALK rearrangement. Pembrolizumab and nivolumab were administered to 51.3% and 48.7, respectively, and 42% received them beyond the third-line chemotherapy. Objective response rate (ORR) was 28.6%. Pembrolizumab group showed numerically higher ORR (30.7%) than the nivolumab group (26.4%), but it was comparable with that of the nivolumab group having PD-L1 TPS >= 50% (32.4%). Median progression-free survival (PFS) and overall survival (OS) were 2.9 (95% CI 0-27.9) and 10.7 months (95% CI 0-28.2), respectively. In multivariable analysis, concordance of TPS >= 50% in both PD-L1 assays and the development of immune-related adverse events (irAEs) were two significant predictors of better ORR, PFS, and OS. EGFR mutation could also predict significantly worse OS outcomes. Conclusion The real-world benefit of later-line anti-PD1 antibodies was comparable to clinical trials in patients with R/M-NSCLC, although patients generally were more heavily pretreated and had poorer ECOG-PS. Concordantly high PD-L1 TPS >= 50% and development of irAE could independently predict better treatment outcomes, while EGFR mutation negatively affected OS. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.title | Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | An, Hyonggin | - |
dc.identifier.doi | 10.1007/s00432-021-03527-4 | - |
dc.identifier.scopusid | 2-s2.0-85100098435 | - |
dc.identifier.wosid | 000613631200001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, v.147, no.8, pp.2459 - 2469 | - |
dc.relation.isPartOf | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - |
dc.citation.title | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - |
dc.citation.volume | 147 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 2459 | - |
dc.citation.endPage | 2469 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordAuthor | Biomarkers | - |
dc.subject.keywordAuthor | Immune-checkpoint inhibitor | - |
dc.subject.keywordAuthor | Non-small cell lung cancer | - |
dc.subject.keywordAuthor | PD-L1 | - |
dc.subject.keywordAuthor | Real-world | - |
dc.subject.keywordAuthor | irAE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.